These include antibodies against cytoskeletal intermediate filaments, cytoplasmic squamous epithelial cells, and nucleolar B23, These antibodies participate in inflammation and activate signal transduction pathways, leading to increased expression of type I collagen genes, promoting fibroblast activation, and inducing typical cGVHD clinical symptoms such as skin sclerosis and pulmonary fibrosis. Here, NPM1 is linked to pulmonary fibrosis.